Success Metrics

Clinical Success Rate
75.0%

Based on 9 completed trials

Completion Rate
75%(9/12)
Active Trials
10(36%)
Results Posted
33%(3 trials)
Terminated
3(11%)

Phase Distribution

Ph not_applicable
1
4%
Ph phase_1
2
7%
Ph phase_2
3
11%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

64.3%

9 of 14 finished

Non-Completion Rate

35.7%

5 ended early

Currently Active

10

trials recruiting

Total Trials

28

all time

Status Distribution
Active(12)
Completed(9)
Terminated(5)
Other(2)

Detailed Status

Completed9
Recruiting8
Terminated3
Active, not recruiting2
Withdrawn2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
28
Active
10
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
N/A1 (16.7%)

Trials by Status

terminated311%
active_not_recruiting27%
recruiting829%
withdrawn27%
enrolling_by_invitation14%
not_yet_recruiting14%
completed932%
unknown27%

Recent Activity

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more
NCT07110246Phase 2

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Recruiting
NCT07226453Phase 2

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

Not Yet Recruiting
NCT04529252

Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases

Active Not Recruiting
NCT04706481

Archival of Human Biological Samples in CU-Med Biobank

Recruiting
NCT05756985

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Recruiting
NCT03555851

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

Recruiting
NCT06774027

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Recruiting
NCT04713657Phase 1

Beta-blocker Administration for Cardiomyocyte Division

Recruiting
NCT06894745Phase 1

PET [89Zr]DFO-starPEG in Solid Tumors

Recruiting
NCT01988285

Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

Active Not Recruiting
NCT02427269

University of North Carolina (UNC) Barrett's Esophagus and Esophageal Cancer Biorepository

Enrolling By Invitation
NCT04022616

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Recruiting
NCT03396926Phase 2

Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer

Completed
NCT03594448

Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients

Terminated
NCT03885167

Identification of Biomarkers in Spinocerebellar Ataxia 3

Completed
NCT02329366

Development of a Cellular Biomarker for the Diagnosis and Treatment of Diabetic Foot Ulcers

Completed
NCT01719146

Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease

Completed
NCT04473183

Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota

Withdrawn
NCT03158298

Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas

Terminated
NCT05292430

B2RAD Translational Medicine Study

Unknown

Drug Details

Intervention Type
PROCEDURE
Total Trials
28